Kiora Pharmaceuticals (NASDAQ:KPRX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) released its quarterly earnings data on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13, FiscalAI reports.

Kiora Pharmaceuticals Trading Up 3.1%

Kiora Pharmaceuticals stock opened at $2.64 on Friday. The company has a market capitalization of $11.70 million, a PE ratio of -1.05 and a beta of -0.38. Kiora Pharmaceuticals has a 12 month low of $1.76 and a 12 month high of $3.01. The stock has a 50-day moving average price of $2.57 and a two-hundred day moving average price of $2.37.

Institutional Investors Weigh In On Kiora Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in KPRX. Two Sigma Investments LP bought a new stake in Kiora Pharmaceuticals during the 3rd quarter worth approximately $33,000. Renaissance Technologies LLC lifted its holdings in shares of Kiora Pharmaceuticals by 71.0% during the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after purchasing an additional 8,800 shares during the period. Citadel Advisors LLC bought a new stake in shares of Kiora Pharmaceuticals in the third quarter worth $125,000. Alyeska Investment Group L.P. acquired a new stake in Kiora Pharmaceuticals in the fourth quarter valued at $152,000. Finally, DRW Securities LLC raised its position in Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after purchasing an additional 73,417 shares during the last quarter. 76.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.